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Abstract
Purpose Recurrent disease following thermal ablation thera-
py is a frequently reported problem. Preoperative identifica-
tion of patients with high risk of recurrent disease might en-
able individualized treatment based on patients’ risk profile.
The aim of the present work was to investigate the role of
metabolic parameters derived from the pre-ablation 18F-FDG
PET/CT as imaging biomarkers for recurrent disease in pa-
tients with colorectal liver metastases (CLM).
Methods Included in this retrospective study were all consec-
utive patients with CLM treated with percutaneous or open
thermal ablation therapy who had a pre-treatment baseline
18F-FDG PET/CT available. Multivariable cox regression for
survival analysis was performed using different models for the
metabolic parameters (SULpeak, SULmean, SULmax, partial
volume corrected SULmean (cSULmean), and total lesion
glycolysis (TLG)) corrected for tumour and procedure
characteristics. The study endpoints were defined as local tu-
mour progression free survival (LTP-FS), new intrahepatic
recurrence free survival (NHR-FS) and extrahepatic recur-
rence free survival (EHR-FS). Clinical and imaging follow-
up data was used as the reference standard.
Results Fifty-four patients with 90 lesions were selected.
Univariable cox regression analysis resulted in eight models.
Multivariable analysis revealed that after adjusting for lesion
size and the approach of the procedure, none of the metabolic
parameters were associated with LTP-FS or EHR-FS.
Percutaneous approach was significantly associated with a
shorter LTP-FS. It was demonstrated that lower values of
SULpeak, SULmax, SULmean , and cSULmean are associated
with a significant better NHR-FS, independent of the lesion
size and number and prior chemotherapy.
Conclusion We found no association between the metabolic
parameters on pre-ablation 18F-FDGPET/CTand the LTP-FS.
However, low values of the metabolic parameters were signif-
icantly associated with improved NHR-FS. The clinical impli-
cation of these findings might be the identification of high-risk
patients who might benefit most from adjuvant or combined
treatment strategies.
Keywords RFA . CLM . PERCIST . Imaging biomarker
Introduction
In recent years, many new treatment modalities have been
established in the field of liver-directed oncologic interven-
tions. Local tumour destruction by means of thermal ablation
therapy has emerged as a safe and effective treatment modality
for patients with colorectal liver metastases (CLM) who are
not surgical candidates [1]. Radiofrequency ablation (RFA)
and Microwave ablation (MWA) are considered safe ablation
Electronic supplementary material The online version of this article
(doi:10.1007/s00259-017-3637-0) contains supplementary material,
which is available to authorized users.
* M. Samim
morsalsamim@gmail.com
1 Department Surgery, University Medical Centre Utrecht,
Heidelberglaan 100, 3508 GA Utrecht, The Netherlands
2 Department Radiology and Nuclear Medicine, University Medical
Centre Utrecht, Heidelberglaan 100, 3508
GA Utrecht, The Netherlands
3 Department of Radiology and Nuclear Medicine, Antoni van
Leeuwenhoek Hospital, Plesmanlaan 121, 1006
BE Amsterdam, The Netherlands
4 Department Surgical Oncology, Antoni van Leeuwenhoek Hospital,
Plesmanlaan 121, 1006 BE Amsterdam, The Netherlands
Eur J Nucl Med Mol Imaging
DOI 10.1007/s00259-017-3637-0
techniques with the ability to accomplish local disease control
as shown in large cohort studies and meta-analyses [2, 3].
Furthermore, thermal ablation is frequently performed com-
bined with concomitant liver resection [4].
Although ablation therapy has been proven to be effective
in many cases, recurrent disease is a frequently reported prob-
lem that jeopardizes patients’ prognosis [1, 5]. Recurrent dis-
ease can be detected in the periphery of the ablation zone after
successful ablation and is referred to as local tumour progres-
sion (LTP) [6]. The reported rates of LTP can be as high as
60% of lesions [1]. Recurrent disease also includes intra- and
extrahepatic disease, occurring in 56% and 44% of patients,
respectively [5, 6]. Identifying robust prognostic biomarkers
might help to predict more accurately which eligible patients
for thermal ablative therapy are at the highest risk for recurrent
disease.
Several studies have investigated the role of 18F-
fluorodeoxyglucose (18F-FDG) positron emission tomography/
computed tomography (PET/CT) for selection and staging of
patients who are considered for ablative treatment of liver lesions
[7]. The role of 18F-FDG PET/CT has only been investigated in
terms of detection of hepatic and extrahepatic lesions for staging
of patients or for treatment evaluation. However, studies have
shown that 18F-FDG PET specific parameters may have a prog-
nostic role in assessing survival of patient with primary or sec-
ondary liver malignancies undergoing curative treatment [8, 9].
This association has also been investigated for other malignan-
cies and demonstrated increased tumour aggressiveness with
higher 18F-FDG uptake in tumour lesions [10–12].
Up to now, the role of metabolic parameters as imaging
biomarkers for recurrent disease following ablative therapy
has not been investigated. However, imaging biomarkers can
offer a risk stratification tool to identify high-risk patients and
allow individualized treatment strategies in order to improve
patients’ survival. The aim of this retrospective cohort study
was to evaluate the role of metabolic parameters in predicting
the prognosis in terms of LTP, intrahepatic, and extrahepatic
recurrent disease in patients with CLM treated by means of
curative-intent thermal ablation therapy. We hypothesized that
an aggressive tumour lesion was associated with a higher met-
abolic activity, resulting in a higher chance of recurrent
disease.
Patients and methods
This retrospective study was reviewed by the institutional re-
view board, and the requirement to obtain informed consent
was waived. We retrospectively identified and included all
consecutive patients with CLM treated with percutaneous or
open RFA or MWA (either alone or combined with liver re-
section) in Antoni van Leeuwenhoek Hospital Amsterdam,
between January 2008 and July 2015. A baseline 18F-FDG
PET/CT scan performed within 2 months prior to ablation
therapy was an inclusion criterion and all ablation procedures
were performed in a curative setting. We excluded tumour
lesions that were not assessable on the baseline 18F-FDG
PET/CT based on visual inspection. The decision for treat-
ment was made during multidisciplinary tumour-board meet-
ing consisting of at least one experienced liver surgeon, an
intervention radiologist, a medical oncologist and a nuclear
physician. The main indications for thermal ablation therapy
were surgical resection (alone) technically not possible due to
multilobar disease or previous liver resection; patient comor-
bidities could not ensure a safe surgical procedure; and patient
preference for minimally invasive treatment. For each proce-
dure, data on clinical and procedural characteristics were col-
lected. Given prior reports of lower 18F-FDG uptake in mu-
cinous type colorectal carcinoma [13], data on histopathology
subtypes (mucinous versus non-mucinous type) of the prima-
ry colorectal carcinoma was collected as well.
Thermal ablation therapy
Percutaneous thermal ablation procedure was performed un-
der epidural anesthesia using CT-guidance for needle position-
ing and evaluation of the ablation zone. The open procedure
was performed under general anesthesia, using ultrasound
guidance for needle positioning. Until 2010, for RFA, the
systems used were Covidien Cool-Tip RF Ablation system
with switching controller. Thereafter, a Cool-Tip RF
Ablation E-series system (Covidien, Mansfield MA, USA)
was used. From August 2012, thermal ablation was also per-
formed by means of MWA using an Emprint ablation system
(Covidien, Mansfield, MA, USA). In case of RFA, either a
single or cluster antenna was used depending on the required
ablation volume. Thermal ablation procedure was performed
by two experienced interventional radiologists and according
to international guidelines [6] ensuring ≥ 5 mm rim of coagu-
lated healthy liver tissue around the tumour lesion.
Follow-up
The standard imaging follow-up schedule consisted of a tri-
phasic CT scan within one month in case of percutaneous
approach or a 18F-FDG PET/CT within 6–8 weeks in case of
open ablation procedure. Subsequently, imaging evaluation
by means of MRI, CT, or 18F-FDG PET/CT took place every
3 months until 1-year follow-up and thereafter biannually. All
patients were followed at least 12 months after the ablation
procedure for detection of recurrent disease. After that, pa-
tients were followed until the last follow-up visit or death.
The follow-up time was defined as the time between the date
of the ablation procedure and the development of recurrent
disease or the last date on which follow-up was performed.
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Overall survival (OS) was defined as interval from ablation to
death.
18F-FDG PET/CTand quantitative analysis
Whole-body 18F-FDG PETwas performed in one institute on
two Gemini TOF scanner (Philips Healthcare, Best, the
Netherlands) at 2 min per bed position in 3-dimensional mode.
Both scanners were EARL compliant. A graph presenting the
recovery curves is included in the supplemental material
(Supplemental material, Fig. S1). A low-dose CT was used
for attenuation correction and anatomical correlation.
Patients were prepared in concordance with the EANM guide-
lines [14] for tumour imaging. 18F-FDG was injected intrave-
nously using a body mass index (BMI) based dosage scheme.
The dose varied between 190 and 240 MBq depending on a
BMI higher or lower than 28. In patients with very high or low
BMI, the administered dose was in consultation with the phy-
sician. Scanning commenced 60 min after administration
(mean 66 +/− 14 min).
The quantitative analysis was performed in concordance
with the PET Response Criteria in Solid Tumours
(PERCIST 1.0) [15] Calculation of the standardized uptake
values corrected for lean body mass (SUL) was performed
using ROVER evaluation software (ABX GmbH, Radeberg,
Germany). The SULpeak, SULmean, partial volume corrected
SULmean (cSULmean), SULmax , and the total lesion glycolysis
(TLG) were collected for all target lesions. The method for
partial volume correction is previously described by Hofheinz
et al. [16].
Delineation of liver lesions can be challenging due to the
relatively high physiological accumulation in healthy liver
tissue. Therefore, the mean SUL of background activity
(SULbckgr) was measured by placing a 3-cm diameter spheri-
cal volume of interest (VOI) in the healthy liver tissue; the
tumour SULpeak was determined in a 1-cm
3 spherical VOIpeak.
According to the PERCIST 1.0 criteria, a baseline tumour
SULpeak has to be ≥1.5 times the SULbckgr of liver tissue plus
two times its standard deviation (SD), otherwise quantifica-
tion can be unreliable. Still, due to the limited number of
patients, all measurements were included in the published
analysis, also if the tumour SULpeak was below this threshold.
A segregated data analysis was performed for measurements
that adhered to the strict PERCIST 1.0 criteria (Supplemental
material, Table S1).
The threshold for the metabolic tumour volume delineation
was set at 70% of the tumour SULpeak (VOI70). However, this
approach sometimes resulted in visually inaccurate delinea-
tions, especially when VOI70 was much smaller than the
VOI1.5bckgr+2SD. In these cases, metabolic tumour volume
was redefined as SULbckgr plus two times SD (n = 4 cases).
The mean tumour SUL (SULmean) is a direct derivative of this
metabolic tumour volume. For the TLG, VOI threshold was
defined as SULbckgr plus two times SD (VOIbckgr+2SD) as rec-
ommended by the PERCIST 1.0. The latter threshold was not
used for the entire dataset since this threshold frequently re-
sulted in inclusion of a large part of the healthy liver tissue in
the VOI, especially when SULpeak was much larger than the
VOI1.5bckgr+2SD. Visual inspection was performed by compar-
ing the VOI with the lesion margins as detected on a recently
performed contrast enhanced CT. Partial volume correction
was implemented for each measurement to account for under-
estimation of the SUL values. For patient-based analysis, the
most metabolically active tumour lesion was used as target
lesion.
Definitions of outcome
Recurrent disease was stratified in site of recurrence: LTP,
intrahepatic, and extrahepatic recurrence. LTP was the prima-
ry endpoint of the study and defined as appearance of tumour
foci at the edge of the ablation zone (up to 1 cm from the
edge), after at least one contrast-enhanced follow-up study
has documented adequate ablation and an absence of viable
tissue in the target tumour surrounding ablation margin [6].
Accordingly, lesions in which residual unablated tumour was
detected on initial follow-up imaging, were excluded from
analysis. Secondary endpoints were new hepatic recurrence
(NHR) and extrahepatic recurrence (EHR). NHR was defined
as new tumour foci outside the ablation zone (>1 cm distance
from the ablation zone) in other parts of the liver and EHRwas
defined as new metastases in other organs than the liver (ex-
cluding patients in whom extrahepatic disease was present at
baseline).
Reference standard
Follow-up imaging (MRI, CT, or 18F-FDG PET/CT) and clin-
ical data were used as the reference standard. The reports of all
post-ablation imaging and the scans were evaluated prospec-
tively by the local investigator in order to evaluate the pres-
ence of LTP, NHR, or EHR. In case of ambiguity between the
imaging reports and the images, the scans were discussed with
an experienced intervention radiologist (W.P.) in order to
reach consensus. The evaluation of follow-up imaging was
blinded for data of the baseline 18F-FDG PET/CT scan.
Statistics
Descriptive analysis was performed to summarize patient
characteristics and treatment characteristics, as well as the
metabolic parameters. The median LTP-free survival (LTP-
FS), NHR-free survival (NHR-FS), and the EHR-free survival
(EHR-FS) were calculated using Kaplan-Meier method. For
LTP-FS, analysis was performed based on a per-lesion basis
and the NHR-FS and EHR-FS analyses were performed on a
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per-patient basis where the target lesion was defined as the
lesion with the highest SULpeak at baseline.
Univariable cox regression analysis was performed for
each metabolic parameter as a risk factor associated with
LTP-FS, NHR-FS, or EHR-FS. The metabolic parameter of
interest was entered in a multivariable model if the P-value
was ≤0.25. Multivariable cox regression analysis was under-
taken to evaluate the prognostic potential of the metabolic
parameter of interest for prediction of LTP-FS, adjusted for
potential effect modifiers such as tumour size, approach of the
procedure (open vs. percutaneous), and type of ablation ther-
apy (RFA vs. MWA). Similar analysis was performed for
NHR-FS and EHR-FS, adjusted for tumour number and size.
The inclusion of covariates in the model was based on clinical
relevance. The event per variable rule was used to decide on
the appropriate number of variables in the model [17]. In order
to investigate the effect of prior chemotherapy on 18F-FDG
uptake of tumour lesions, a subset analysis was performed in
the chemo-naïve patients. Chemo-naïve was defined as no
chemotherapy at least one year prior to ablation therapy.
The proportional hazard assumption for the cox regression
model was tested by means of a goodness-of-fit test using chi-
square statistics computed for each variable in the model, and
adjusted for the other variables in the model. To address the
problem of multicollinearity, a correlation coefficient matrix
was calculated, with values >0.8 suggesting collinearity be-
tween independent variables. In order to obtain clinical rele-
vant results, the median value of the metabolic parameters in
the cohort was initially used to retrieve a cut-off value for each
parameter. In case of LTP-FS, the median values were based
on a per-lesion analysis and in case of NHR-FS and EHR-FS,
the median values were based on a per-patient analysis. The
multivariable cox regression analysis was performed again
including the dichotomized variables. Differences in the sur-
vival of the two groups (low and high metabolic value), ad-
justed for covariates in the model was demonstrated using
Kaplan-Meier curves along with the 1-year survival rates.
Statistical analyses were performed using RStudio version
3.1.2 open-source software. A P-value <0.05 was considered
as statistically significant.
Results
Patient and tumour characteristics
A total of 54 patients underwent 60 thermal ablation proce-
dures and met the inclusion criteria for the study. During the
60 ablation procedures, 90 lesions were ablated. Table 1 sum-
marizes the demographics and the tumour characteristics. The
patient characteristics are based on the number of patients, the
tumour characteristics are based on the lesion numbers and the
procedure characteristics based on the number of procedures.
Data on histopathology subtypes of the primary colorectal
carcinoma showed only one patient with the mucinous type.
RFAwas used for ablation of 72 lesion (80%) and MWA for
ablation of 18 (20%) lesion. Of the 60 ablation procedures, 31
(52%) were performed open and 29 (48%) percutaneously.
The number of lesion on the preoperative imaging ranges
between one and four lesions and of these, 17 lesions were
resected during a combined procedure (Table 1). The median
lesion size was 18 mm (7–55 mm) and 14 (23%) lesions were
located ≤1 cm from large vessels. In three patients, incomplete
ablation/residual disease was detected on the first follow-up
scan in four lesions, so these lesions were excluded from the
analysis for LTP-FS. Although all patients had liver dominant
disease, extrahepatic disease was present at baseline in 11
patients (20%). These patients were excluded from the analy-
sis for the EHR-FS. According to the PERCIST 1.0 criteria,
68 out of 90 lesions were defined as assessable target lesions
(baseline tumour SULpeak ≥1.5 times the SULbckgr of liver
tissue plus two times its SD). This resulted in 47 patients for
the NHR-FS analysis and 38 patients for the EHR-FS analysis
according to PERCIST 1.0 (Supplemental material). Figure 1
demonstrates PET/CT imaging of a patient with high versus
low 18F-FDG uptake in the tumour lesion.
Survival characteristics
The median follow-up time was 29.3 months (range 5.8–
91.8 months). Lesion-based analyses resulted in a LTP rate
of 46.5% (40 out of 86 lesions). Of these, 36 out of 86
(41.9%) were identified within 1 year and 20 out of 86
(23.3%) were identified within 6 months following the abla-
tion procedure. The 6-month and 1-year LTP-FS were 80.2%
(72.2–89.1) and 58.1% (48.3–69.7), respectively. The median
number of follow-up moments within 1-year was 4.5 (range
3–8) in patients that did not develop LTP and 4 (range 2–8) in
patients with LTPwithin 1 year. Thirty-two patients developed
NHR (59.0%) and 24 out of 43 patients (56.0%), developed
EHR during the course of the disease. The 1-year and 3-year
NHR-FS and EHR-FSwere 47.4% (35.7–63.0), 37.1% (25.4–
54.0) and 62.6% (49.7–79.0), 41.9% (29.1–60.4), respective-
ly. Twenty-one patients (39%) died during the entire follow-
up. The median OS was 49.3 months with a 1-year and 5-year
survival rate of 94.1% (87.9–100.0) and 28.0% (13.6–57.6),
respectively.
Cox regression analysis
The univariable analysis resulted in three models for LTP-FS
analysis, four models for NHR-FS and one model for EHR-FS
(Tables 2 and 3). The type of ablation treatment (RFA vs.
MWA) did not meet the proportional hazard assumption and
was not found to be an effect-modifier for the relation between
the metabolic activity and LTP-FS. Therefore, this variable
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was not included in the multivariable model. The chi-square
test resulted in a P-value >0.05 for the remaining categorical
variables in the models. The correlation coefficient between
the metabolic parameters of the hepatic metastases was only
weakly correlated with lesion size (r <0.40) suggesting no
complications caused by multicollinearity in the models.
Multivariable analysis revealed that after adjusting for le-
sion size and the approach of the procedure, none of the met-
abolic parameters were associated with LTP-FS (Table 3).
Percutaneous approach was significantly associated with a
shorter LTP-FS (hazard ratio of 2.3, P <0.01), independent
of the lesion size. Models 4–7 demonstrated that low values
of SULpeak, SULmax, SULmean , and cSULmean are significant-
ly associated with a better NHR-FS, independent of the lesion
size and number (Table 3). In other words, new hepatic lesions
were earlier observed in patients with more metabolically ac-
tive tumours. Of these, the SULmean had the highest hazard
ratio for a shorter NHR-FS (model 6, hazard ratio of 1.60,
P = 0.003). Based on the hazard ratio and the significance
level, the cSULmean did not seem to be superior compared to
the SULmean (Table 3). The results of the multivariable analy-
sis did not reveal any association between SULpeak , adjusted
for lesion size, and the EHR-FS. The multivariable analysis
was performed separately in data according to PERCIST 1.0
and results were in line with the results of the analysis in the
entire dataset (Supplemental material, Table S1).
The chosen cut-off values for SULpeak, SULmax, SULmean ,
and cSULmean were 5.0, 5.6, 4.2, and 6.8, respectively.
Multivariable cox regression analysis demonstrated a hazard
ratio of respectively 2.7, 2.5, 2.4, and 2.1 for NHR-FS, inde-
pendent of lesion size and number (Table 4). This can be
interpreted as a 2.7 times higher risk of developing
intrahepatic disease per unit time in patients with SULpeak
>5.0. Only the cut-off value for cSULmean did not remain
significant after dichotomizing the metabolic parameter
(P = 0.053). Kaplan-Meier survival curves were plotted for
NHR-FS stratified for high and low SULpeak, SULmax , and
SULmean, adjusted for tumour number and size (Fig. 2). The
mean 1-year NHR-free rates for the high versus low values of
the metabolic parameters was 35% versus 61%, respectively.
Additionally, Kaplan-Meier analysis was performed in order
to evaluate differences in OS stratified for high versus low
value of the SULpeak and the SULmean. Figure 3 illustrates
the significant differences in OS of patients with a preopera-
tive high versus low value of the SULpeak and the SULmean.
The calculated 3-year survival rates were 83.3% versus 40.3%
in the low versus high SULpeak group. Accordingly, the 3-year
survival rate in the low versus high SULmean group was 73.5%
versus 45.4% respectively.
Analysis in chemo-naïve patients
Eight patients (15%) had received systemic therapy at least 1
year prior to ablation therapy. The univariable and multivari-
able analysis was repeated in the chemo-naïve patients
(Supplemental material, Table S2). The univariable analysis
in the chemo-naïve patients resulted in four models corre-
sponding with models 4, 5, 6, and 7 (Table 3). The results of
the multivariable analysis in the chemo-naïve patients showed
that low values of SULpeak, SULmean , and cSULmean, but not
SULmax, were significantly associated with a better NHR-FS.
However, the dichotomized values of the SULpeak, SULmean ,
Table 1 Demographics and tumour characteristics
Characteristic N (%)
Number of patients 54
Number of procedures 60
Number of lesions 90
Age (median), year 62 (40–84, IQR 14)
Gender (Male/female) 33 (61)/21 (39)









Comorbidity (n = 54)
Hearth disease 5 (9)
Pulmonary disease 4 (7)
Renal disease 1 (2)
Other 9 (17)
Extrahepatic disease (n = 54) 11 (20)
Pulmonary 8 (15)
Lymph node 2 (4)
Peritoneal 1 (2)
Prior chemotherapy 28 (52)
Within 1 year from treatment 8 (15)
Adjuvant chemotherapy
Within 6 months after treatment 11 (20)
Directly after treatment 2 (4)










Lesion size in mm (median, n = 90) 18 mm, range 7–55 mm, IQR
11 mm
Distance to large vessel ≤1 cm (n = 90) 14 (23)
Metabolic parameter (based on all lesions)
SULpeak 4.8 (1.7–10.2, IQR 2)
SULmean 4.0 (1.6–9.1, IQR 1.6)
cSULmean 6.6 (2.3–19.8, IQR 3.7)
SULmax 5.4 (1.9–12.6, IQR 2.3)
TLG 23.7 (2.8–305.2, IQR 31.9)
SULmean of normal liver 2.0 (1.3–2.4, IQR 0.3)
a Of these, 17 out of 107 lesions were resected during an combined
procedure. ASA American Society of Anesthesiologists; IQR interquar-
tile range;MWAmicrowave ablation; RFA radiofrequency ablation; TLG
total lesion glycolysis
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and cSULmean did not remain significant in the multivariable
analysis (Table 4).
Discussion
This study showed that the metabolic parameters calculated
based on the pre-ablation 18F-FDG PET/CT were not associ-
ated with LTP-FS. In the multivariable model, the percutane-
ous approach of the procedure remained the most significant
predictor of LTP. An important finding was that the metabolic
parameters were independent prognostic risk factors for NHR-
FS, even in chemo-naïve patients. Remarkably, none of the
metabolic parameters were associated with EHR-FS.
Our results suggest that the aggressiveness of the tumour
lesions as expressed by means of the metabolic activity is not
associated with shorter LTP-FS after thermal ablation therapy.
A possible explanation might be that appearance of LTP
highly depends on technical aspects of the procedure and tu-
mour size, rather than the metabolic activity. Evidently, the
success of ablation therapy greatly depends on the correct
positioning of the ablation probe and visibility of the tumour
lesion [18]. During an open procedure, localization of the
lesion is done by means of intraoperative ultrasound. Use of
ultrasound imaging eliminates attenuation by the skin and
subcutaneous tissue and ensures a wider window, resulting
in an improved visibility and image resolution. Another ben-
efit of the open procedure is the improved controlled position-
ing of the probe allowing insertion of the probe at different
angles with mobilization of the liver if necessary [18].
Despite the differences in the LTP rate, percutaneous abla-
tion is considered the least invasive method and is recom-
mended over the open approach due to the increased mortality
and morbidity of the latter [3]. Obviously, this does not count
for an ablation procedure that is combined with surgical liver
resection [3] Moreover, it would be of interest whether and
















































































































EHR-FS extrahepatic recurrence free survival; LTP-FS local tumour progression free survival; NHR-FS new hepatic recurrence free survival. *Relevant
metabolic parameters used in the multivariable models are marked
Fig. 1 PET/CT imaging of a
patient with high (left panel)
versus low (right panel) 18F-FDG
uptake in the tumour lesion with
the median SULpeak value as cut-
off point (median SULpeak of 4.8)
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how the OS or the progression free survival is affected by the
approach of the procedure. Unfortunately, our study design
did not allow for an analysis for this purpose.
The reported LTP rates after ablation therapy vary widely
between studies and comparison between cohorts is hampered
due to analysis on a per-lesion or a per-patient basis. Reported
lesion-based LTP rate is up to 43% [3] for open ablation and up
to 52% for the percutaneous approach [3, 19]. Although higher
than expected, the LTP rate in our cohort lies within the range
of previous reported rates. Besides the approach of the proce-
dure, the diameter of the lesion (>3 cm) and minimal ablation
margin size are important known risk factors [19, 20]. In our
cohort, lesion size was not considered as an exclusion criterion.
As a result, lesions measuring >3 cm were also included which
might explain our LTP rate. Furthermore, current evidence
shows that an ablation margin between 5 and 10 mm is a
Table 3 Multivariable cox regression models for LTP-FS (models 1–3), NHR-FS (models 4–7) and EHR-FS (model 8)
Model Outcome variable Covariates Hazard ratio (95% CI) P Hazard ratio (95% CI) P
All patients Chemo-naive patients

































































































CI confidence interval; CNChemo-naïve patients; EHR-FS extrahepatic recurrence free survival; LTP-FS local tumour progression free survival; NA not
applicable; NHR-FS new hepatic recurrence free survival
Table 4 Multivariable cox
regression models for NHR-FS
with dichotomized values of the
metabolic parameters
Model Covariates Hazard ratio (95% CI) P Hazard ratio (95% CI) P
All patients Chemo-naive patients
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prognostic factor for shorter LTP-FS and ideally, an ablation
margin ≥10 mm should be endeavored [19]. Unfortunately, an
ablation margin of ≥5 mm was aimed in our clinic.
The prognostic value of the metabolic parameters for
time to progression of intrahepatic recurrence is an impor-
tant finding since patients’ prognosis after ablation thera-
py seems to be more depending on intrahepatic recurrence
rather than LTP. It was shown that LTP alone does not
significantly affect the OS of patients treated by means of
ablation therapy, but the pattern of disease recurrence
does [21]. The OS of patients with LTP combined with
intrahepatic recurrence was found to be worse compared
to patients with LTP alone. A possible explanation is that
a repeated ablation therapy, hence curative treatment, is
still feasible in majority of patients with timely detected
LTP.
Previous studies reported the prognostic significance of
metabolic parameters for the survival of patients with sur-
gically treated CLM [8, 22–24]. However, to our
knowledge, this is the first study that investigated this
for patients with CLM treated by means of curative-
intent thermal ablation with stratified results for site of
recurrence. We showed that a higher metabolic value is
significantly associated with a worse NHR-FS. In case of
a the SULpeak >5.0, multivariable analysis showed a 2.7
times higher risk of developing intrahepatic disease per
unit time. Since all PET imaging was performed using
an EARL compliant PET scanner, the resulted cut-off
values for the metabolic parameters can be useful in other
EARL accredited centers [25].
Although we included only patients treated with thermal
ablation therapy, our results are consistent with findings by
other authors [8, 22–24]. A recent meta-analysis pooled the
data on the prognostic significance of metabolic parameters
and patients’ survival and found a significant association be-
tween a high pretreatment SUVand a poor OS (pooled hazard
ratio of 1.24, 95% CI 1.06–1.45) [26]. Lee et al. investigated
the prognostic significance of pre-treatment metabolic values
Fig. 2 Adjusted Kaplan-Meier curves for NHR-FS with dichotomized
values of the metabolic parameters SULpeak, SULmean , and SULmax. The
1-year NHR-free rate was 62.2% (95%CI 46.1–83.9) and 35.2% (95%CI
20.8–59.9) for SULpeak lower and higher than 5.0 respectively, 60.1%
(95% CI 44.1–81.9) and 36.6% (95% CI 21.6–61.9) for SULmean lower
and higher than 4.2 and 61.2% (95% CI 45.3–82.9) and 61.7% (95% CI
45.7–83.2) and 34.4% (95% CI 20.0–59.2) for SULmax lower and higher
than 5.6, respectively
Fig. 3 Kaplan-Meier curves for OS with dichotomized values of the metabolic parameters SULpeak (left) and SULmean (right)
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and found a significant association between the SUVpeak of
hepatic metastases and the recurrence free survival [8]. Other
researchers conducted similar studies, but discrepancy in the
reported results existed. According to Riedl et al. [22], the
SUVmax measured on the pre-operative
18F-FDG PET was
associated with a significant shorter OS, while Muralidharan
et al. [24] did not find any association between the SUVmax or
the SUVmean and OS or recurrence free survival. The differ-
ences in the prognostic ability of the metabolic parameters
reported by various authors might be the result of variability
of technical and biological factors as well as heterogeneity of
the population in the studies [27].
Nevertheless, the findings from previous studies, as well as
present study show that higher metabolic activity of the tu-
mour lesion is associated with a relatively poor outcome. PET
imaging visualizes the increased glucose use by tumour cells
using 18F-FDG as tracer. However, the cellular and molecular
mechanisms that determine 18F-FDG uptake are poorly under-
stood. Traditionally, histopathological characteristics are con-
sidered as reliable markers for biological aggressiveness [28].
The latter is considered a major determinant of clinical out-
come of patients [28].
Careful selection of candidates for thermal ablation ther-
apy is important and recommended by the international
expert panel [3]. To maintain good survival rates, similar
as after surgical resection of liver metastases, adjuvant sys-
temic therapy should be acknowledged after curative ther-
mal ablation [3]. However, it is not clear which patients
benefit most from adjuvant systemic treatment. Previous
studies showed the beneficial effect of adjuvant chemo-
therapy on the progression free survival [29–31]. The re-
sults of a randomized trial by Ruers et al. showed a signif-
icant improvement in progression free survival in patients
treated with ablation therapy combined with systemic ther-
apy compared to systemic therapy alone [29]. In the cur-
rent study, a large difference in the 1-year NHR-free rate of
patients with a high versus low metabolic value (35% ver-
sus 61%) was demonstrated. These findings might indicate
that especially patients with highly metabolic active tu-
mours, as measured based on the pre-procedural 18FDG-
PET/CT, might benefit most from adjuvant systemic treat-
ment or combined therapies.
In this study, we found no association between the meta-
bolic activity and the EHD-FS. To our knowledge, no other
studies have investigated the correlation of metabolic activity
and extrahepatic disease recurrence. Other studies that inves-
tigated possible predictors of extrahepatic recurrence after
curative-intent surgery, found the following characteristics as-
sociated with an increased risk: primary rectal tumour site,
primary tumour lymph node metastasis, hepatic tumour size
>5 cm, hepatic tumour number >4, as well as receipt of che-
motherapy [32–35]. The lack of association between metabol-
ic activity and extrahepatic disease in our cohort is remarkable
as our results demonstrated a significant association between
metabolic activity and OS. A possible explanation for our
findings is the small sample size that was used for this analy-
sis. Hence, the association between the metabolic activity and
extrahepatic recurrence after curative-intent surgery needs to
be further addressed in future studies with larger cohorts.
There are limitations to this study. The retrospective nature
introduces the risk of selection bias. However, we used clearly
defined inclusion and exclusion criteria and included all con-
secutive patients to mitigate this problem. The threshold for
the metabolic tumour volume delineation was set at 70% of
the tumour SULpeak unless this approach resulted in visually
inaccurate delineation. This was the case in four patients for
whom a different threshold for delineation (SULbckgr+2SD) was
used. The use of different thresholds might have introduced
bias in the reported results. However, the segregated analysis
for measurements according to the PERCIST 1.0 criteria
showed similar results as in the entire dataset. Also, the
VOI70 threshold for tumour volume delineation was not ac-
cording to EANM guidelines [13]. The post injection time
varied quite (66 +/− 14min) between patients whichmay have
affected the tumour to normal-liver uptake ratio and subse-
quently the resulted metabolic value. Finally, although the
SUV corrected for body weight is more often used in the
clinical practice, we used the SUL values instead, because
the latter is more consistent from patient to patient [36]
There is cumulative evidence on the prognostic signifi-
cance of pretreatment 18F-FDG PET/CT. The call for more
individualized approach to cancer treatment challenges future
studies to investigate prospectively whether risk stratification
of patients by means of metabolic parameters will lead to
change of management and significant improvement in pa-
tients’ survival. Moreover, it should be recognized that the
benefit of PET imaging can be extended by using different
tracers for different biological features such as hypoxia level,
which in turn is associated with negative effect on prognosis
[37–39]. Perhaps this can lead to promising risk stratification
tools that combine different biological imaging markers based
on an entirely non-invasive method.
Conclusion
Our findings add to the growing knowledge of the value of
18F-FDG PET/CT in the staging and evaluation setting of
patients with CLM. We found no association between the
metabolic parameters on pre-ablation 18F-FDG PET/CT and
the LTP-FS. However, low values of the metabolic parameters
were significantly associated with improved NHR-FS. In the
era of tailored approach to patient care, the clinical implication
of these findings is the identification of patients who might
benefit most from adjuvant or combined treatment strategies.
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